Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

被引：36
|
作者：
Yu, Evan Y.
Massard, Christophe
Retz, Margitta
Tafreshi, Ali
Carles Galceran, Joan
Hammerer, Peter
Fong, Peter C. C.
Shore, Neal D.
Joshua, Anthony
Linch, Mark David
Gurney, Howard
Romano, Emanuela
Augustin, Marinela
Piulats, Josep M.
Wu, Haiyan
Schloss, Charles
Poehlein, Christian Heinrich
De Bono, Johann S.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Gustave Roussy Canc Campus, Villejuif, France
[3] Univ Paris Sud, Villejuif, France
[4] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany
[5] Univ Wollongong, Wollongong, NSW, Australia
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] Acad Hosp Braunschweig, Braunschweig, Germany
[8] Auckland City Hosp, Auckland, New Zealand
[9] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[10] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia
[11] UCL, Inst Canc, London, England
[12] Macquarie Univ Hosp, Sydney, NSW, Australia
[13] Inst Curie, Paris, France
[14] Klinikum Nurnberg, Nurnberg, Germany
[15] Catalan Canc Inst, Barcelona, Spain
[16] Merck & Co Inc, Kenilworth, NJ USA
[17] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.145
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
145
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis
    Yu, E.
    Piulats, J. M.
    Gravis, G.
    Fong, P.
    Todenhoefer, T.
    Laguerre, B.
    Arranz, J.
    Oudard, S.
    Massard, C.
    Stoeckle, M.
    Nordquist, L. T.
    Carles, J.
    Huang, M.
    Li, Y.
    Qiu, P.
    Poehlein, C. H.
    Schloss, C.
    de Bono, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S387 - S387
  • [22] KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)-naive patients with metastatic castration-resistant prostate cancer (mCRPC)
    Todenhoefer, T.
    Piulats, J. M.
    Ferrario, C.
    Linch, M. D.
    Stoeckle, M.
    Laguerre, B.
    Arranz, J. A.
    Fong, P. C. C.
    Berry, W. R.
    Emmenegger, U.
    Mourey, L.
    Mar, N.
    Appleman, L. J.
    Joshua, A. M.
    Conter, H. J.
    Li, X. T.
    Schloss, C.
    Poehlein, C. H.
    De Bono, J. S.
    Yu, E. Y.
    EUROPEAN UROLOGY, 2022, 81 : S789 - S790
  • [23] Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC)
    Antonarakis, Emmanuel S.
    Piulats, Josep M.
    Gross-Goupil, Marine
    Goh, Jeffrey C.
    Vaishampayan, Ulka N.
    De Wit, Ronald
    Alanko, Tuomo
    Fukasawa, Satoshi
    Tabata, Kenichi
    Feyerabend, Susan
    Berger, Raanan
    Wu, Helen
    Kim, Jeri
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [24] Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer
    Vaishampayan, Ulka N.
    Fontana, Joseph
    Heilbrun, Lance K.
    Smith, Daryn
    Heath, Elisabeth
    Dickow, Brenda
    Figg, William D.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) : 31.e25 - 31.e33
  • [25] KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)-New data after an additional 1 year of follow-up.
    Appleman, Leonard Joseph
    Kolinsky, Michael Paul
    Berry, William R.
    Retz, Margitta
    Mourey, Loic
    Piulats, Josep M.
    Romano, Emanuela
    Gravis, Gwenaelle
    Gurney, Howard
    De Bono, Johann S.
    Boegemann, Martin
    Emmenegger, Urban
    Joshua, Anthony M.
    Massard, Christophe
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Li Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [26] KEYNOTE-365 COHORT D: PEMBROLIZUMAB PLUS ABIRATERONE ACETATE AND PREDNISONE IN PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Piulats, Josep
    Ferrario, Cristiano
    Linch, Mark
    Stoeckle, Michael
    Laguerre, Brigitte
    Arranz, Jose
    Todenhoefer, Tilman
    Fong, Peter
    Berry, William
    Emmenegger, Urban
    Mourey, Loic
    Mar, Nataliya
    Appleman, Leonard
    Joshua, Anthony
    Conter, Henry
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian
    De Bono, Johann
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A378 - A378
  • [27] Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Petrylak, Daniel P.
    Ratta, Raffaele
    Matsubara, Nobuaki
    Korbenfeld, Ernesto Pablo
    Gafanov, Rustem
    Mourey, Loic
    Fer, Tilman Todenho Spacing Diaeresis
    Gurney, Howard
    Kramer, Gero
    Bergman, Andre M.
    Zalewski, Pawel
    De Santis, Maria
    Armstrong, Andrew J.
    Gerritsen, Winald R.
    Pachynski, Russell Kent
    Saretsky, Todd L.
    Ghate, Sameer R.
    Li, Xin Tong
    Schloss, Charles
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [28] Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer (mCRPC).
    Yu, Evan Y.
    Wu, Haiyan
    Schloss, Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] PEMBROLIZUMAB PLUS ENZALUTAMIDE IN ABIRATERONE-PRETREATED PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: UPDATED RESULTS FROM KEYNOTE-365 COHORT C
    Yu, Evan Y.
    Fong, Peter
    Piulats, Josep M.
    Appleman, Leonard
    Conter, Henry
    Feyerabend, Susan
    Shore, Neal
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Gurney, Howard
    Retz, Margitta
    Romano, Emanuela
    Mourey, Loic
    de Bono, Johann S.
    Kam, Audrey
    Emmenegger, Urban
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian
    Berry, William
    JOURNAL OF UROLOGY, 2020, 203 : E368 - E368
  • [30] KEYNOTE-921: Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Petrylak, D. P.
    Li, B.
    Schloss, C.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2019, 30 : 351 - 351
12345